Go to article: Home | The path of yeast resistanceGo to article: NSFGo to article: EditorialGo to article: ContentsGo to article: NewsGo to article: Emirates SkyCargoGo to article: The pharma industry briefingGo to article: A resolution for the new decade: resolve the US opioid crisisGo to article: Eurofins CDMOGo to article: Precision medicine: what barriers remain?Go to article: Can recyclable packaging turn the pharma industry green?Go to article: Phoenix Company InsightGo to article: PhoenixGo to article: Vertex’s Trikafta: treating the genetic basis of cystic fibrosis Go to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Q&A: talking innovation with the Association for the Cannabinoid IndustryGo to article: Yeast of burden: how to develop better antifungal drugsGo to article: Loose lips bring risks: protecting pharma against leaks and fraud Go to article: Why are patients struggling to access life-saving immune globulin?Go to article: MimotopesGo to article: Deals in brief powered by GlobalDataGo to article: Nolato Company Insight Go to article: NolatoGo to article: The key list powered by GlobalDataGo to article: EventsGo to article: Next issue